Инфекции мочевых путей у больных сахарным диабетом 2-го типа с фармакологической глюкозурией

Стуров Н.В., Попов С.В., Мампория Н.К., Магер А.А. Инфекции мочевых путей у больных сахарным диабетом 2-го типа с фармакологической глюкозурией Терапевтический архив. 2020; 92 (11): 106–109. DOI:10.26442/00403660.2020.11.000581

________________________________________________

Sturov N.V., Popov S.V., Mamporia N.K., Mager A.A. Urinary tract infections in patients with type 2 diabetes mellitus with pharmacological glucosuria Therapeutic Archive. 2020; 92 (11): 106–109. DOI: 10.26442/00403660.2020.11.000581

Читать PDF

Аннотация

Селективные ингибиторы натрий-глюкозного котранспортера относят к новому классу препаратов для лечения сахарного диабета 2-го типа (СД2). Механизм их действия основан на инсулинонезависимом снижении реабсорбции глюкозы в проксимальных почечных канальцах, что ведет к стимуляции экскреции ее с мочой и, соответственно, к снижению концентрации глюкозы в плазме крови. Препараты данной группы демонстрируют эффективность при лечении СД2, однако их применение может быть сопряжено с повышенной частотой развития инфекций мочевых путей. Фармакологическая глюкозурия, приводящая к снижению концентрации глюкозы в крови, создает предпосылки для возникновения инфекций мочевых путей. Инфекции мочевых путей и половых органов являются наиболее часто встречающимся нежелательным явлением, ассоциированным с применением ингибиторов натрий- глюкозного котранспортера. В представленном обзоре литературы за 2016–2019 гг. проанализирована взаимосвязь инфекций мочевых путей у больных СД2 с терапией ингибиторами натрий-глюкозного котранспортера.

Ключевые слова: ингибиторы натрий-глюкозного котранспортера 2-го типа, сахарный диабет 2-го типа, инфекции мочевых путей.

________________________________________________

Selective inhibitors of sodium-glucose cotransporter belong to a new class of drugs for the treatment of type 2 diabetes mellitus. The mechanism of their action is based on insulin-independent reduction of glucose reabsorption in the proximal renal tubules, which leads to stimulation of its excretion in the urine and, accordingly, to a decrease in the concentration of glucose in the blood plasma. Drugs of this group demonstrate effectiveness in the treatment of type 2 diabetes, but their use may be associated with an increased frequency of urinary tract infections. Pharmacological glucosuria, which leads to a decrease in the concentration of glucose in the blood, creates the preconditions for the occurrence of urinary tract infections. Urinary tract and genital infections are the most common adverse events associated with the use of sodium-glucose cotransporter inhibitors. In the presented literature review for 2016–2019, the relationship between urinary tract infections in patients with type 2 diabetes mellitus and therapy with sodium-glucose cotransporter inhibitors was analyzed.

Keywords: type 2 sodium-glucose cotransporter inhibitors, type 2 diabetes mellitus, urinary tract infections.

Список литературы

1. Figueiredo IR, Rose SCP, Freire NB, et al. Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: a systematic review. Rev Assoc Med Bras. 1992. 2019 Feb;65(2):246-52. doi: 10.1590/1806-9282.65.2.246
2. Kushner P. Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetes. Womens Health (Lond). 2016;12(3):379-88. doi: 10.2217/whe-2016-0001
3. Rizzi M, Trevisan R. Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors. Nutr Metab Cardiovasc Dis. 2016;26(11):963-70. doi: 10.1016/j.numecd.2016.07.006
4. Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017;7(1):2824. doi: 10.1038/s41598-017-02733-w
5. Shestakova MV, Wilding JPH, Wilpshaar W, et al. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. Diabetes Res Clin Pract. 2018;146:240-50. doi: 10.1016/j.diabres.2018.10.018
6. Rodbard HW, Seufert J, Aggarwal N, et al. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes Obes Metab. 2016;18(8):812-9. doi: 10.1111/dom.12684
7. Terauchi Y, Tamura M, Senda M, et al. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. Diabetes Obes Metab. 2017;19(10):1397-407. doi: 10.1111/dom.12957
8. Sinclair AJ, Bode B, Harris S, et al. Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. J Am Geriatr Soc. 2016;64(3):543-52. doi: 10.1111/jgs.14028
9. Qiu R, Balis D, Xie J, et al. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Curr Med Res Opin. 2017 Mar;33(3):553-62. doi: 10.1080/03007995.2016.1271780
10. Storgaard H, Gluud LL, Bennett C, et al. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS One. 2016 Nov 11;11(11):e0166125. doi: 10.1371/journal.pone.0166125
11. Trujillo JM, Nuffer WA. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes. Pharmacotherapy. 2017;37(4):481-91. doi: 10.1002/phar.1903
12. Dandona P, Chaudhuri A. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician. Int J Clin Pract. 2017;71(5):e12937. doi: 10.1111/ijcp.12937
13. Donnan JR, Grandy CA, Chibrikov E, et al. Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials. CMAJ Open. 2018;6(4):E594-E602. doi: 10.9778/cmajo.20180111
14. Li D, Wang T, Shen S, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(3):348-55. doi: 10.1111/dom.12825
15. Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783-94. doi: 10.1111/dom.12670
16. Jabbour S, Seufert J, Scheen A, et al. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab. 2018 Mar;20(3):620-8. doi: 10.1111/dom.13124
17. Feng M, Lv H, Xu X, et al. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019;98(30):e16575. doi: 10.1097/MD.0000000000016575
18. Puckrin R, Saltiel MP, Reynier P, et al. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55(5):503-14. doi: 10.1007/s00592-018-1116-0
19. Chawla G, Chaudhary KK. A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. Diabetes Metab Syndr. 2019 May – Jun;13(3):2001-8. doi: 10.1016/j.dsx.2019.04.035
20. Kohler S, Salsali A, Hantel S, et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin Ther. 2016 Jun;38(6):1299-313. doi: 10.1016/j.clinthera.2016.03.031
21. Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016 Sep;59(9):1860-70. doi: 10.1007/s00125-016-4008-2
22. Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019;18(4):295-311. doi: 10.1080/14740338.2019.1602116
23. Esteban-Jiménez O, Navarro-Pemán C, Urieta-González L. Seguridad de los iSGLT-2. Revisión de las reacciones adversas notificadas a nivel nacional [Safety of SGLT2 inhibitors. A review of the adverse drug reactions registered in a national database]. Semergen. 2018;44(1):23-9. doi: 10.1016/j.semerg.2017.10.003
24. Arakaki RF. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. Postgrad Med. 2016;128(4):409-17. doi: 10.1080/00325481.2016.1167570
25. Yang L, Zhang L, He H, et al. Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in East Asians with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Ther. 2019 Oct;10(5):1921-34. doi: 10.1007/s13300-019-0674-7
26. Gadzhanova S, Pratt N, Roughead E. Use of SGLT2 inhibitors for diabetes and risk of infection: analysis using general practice records from the NPS MedicineWise MedicineInsight program. Diabetes Res Clin Pract. 2017;130:180-5. doi: 10.1016/j.diabres.2017.06.018
27. Bersoff- Matcha SJ, Chamberlain C, Cao C, et al. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med. 2019 Jun 4;170(11):764-9. doi: 10.7326/M19-0085

________________________________________________

Авторы

Н.В. Стуров1, С.В. Попов1,2, Н.К. Мампория2, А.А. Магер1

1 ФГАОУ ВО «Российский университет дружбы народов», Москва, Россия;
2 АНО «Центральная клиническая больница Святителя Алексия» Московской патриархии, Москва, Россия

________________________________________________

N.V. Sturov1, S.V. Popov1,2, N.K. Mamporia2, A.A. Mager1

1 People’s Friendship University of Russia, Moscow, Russia;
2 Central Clinical Hospital of St. Alexy of the Moscow Patriarchate, Moscow, Russia

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.